Comparison of new paediatric fixed-dose combination of lamivudine/abacavir dispersible tablets with Epzicom®

Trial Profile

Comparison of new paediatric fixed-dose combination of lamivudine/abacavir dispersible tablets with Epzicom®

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2015

At a glance

  • Drugs Lamivudine/abacavir (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Mylan
  • Most Recent Events

    • 16 Sep 2015 New trial record
    • 22 Jul 2015 Results presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top